

# Isabelle Opitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/431175/publications.pdf>

Version: 2024-02-01

161  
papers

4,094  
citations

117453

34  
h-index

149479

56  
g-index

171  
all docs

171  
docs citations

171  
times ranked

5009  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. <i>Pulmonary Circulation</i> , 2022, 12, e12001.	0.8	7
2	The impact of gender bias in cardiothoracic surgery in Europe: a European Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery survey. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1390-1399.	0.6	8
3	Dual-Energy CT Pulmonary Angiography for the Assessment of Surgical Accessibility in Patients with Chronic Thromboembolic Pulmonary Hypertension. <i>Diagnostics</i> , 2022, 12, 228.	1.3	2
4	Sarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma. <i>Diagnostics</i> , 2022, 12, 99.	1.3	3
5	Prospective validation and extension of the Multimodality Prognostic Score for the treatment allocation of pleural mesothelioma patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	3
6	Surgical management of lung cancer during the COVID-19 pandemic – a narrative review and single-centre report. <i>Swiss Medical Weekly</i> , 2022, 152, w30109.	0.8	3
7	BSREM for Brain Metastasis Detection with 18F-FDG-PET/CT in Lung Cancer Patients. <i>Journal of Digital Imaging</i> , 2022, 35, 581-593.	1.6	5
8	A Delphi Consensus report from the "Prolonged Air Leak: A Survey" study group on prevention and management of postoperative air leaks after minimally invasive anatomical resections. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	5
9	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	0.5	44
10	Ex Vivo Lung Perfusion with Î²-Nicotinamide Adenine Dinucleotide (NAD+) Improves Ischemic Lung Function. <i>Antioxidants</i> , 2022, 11, 843.	2.2	5
11	Is There a Prognostic Difference Between Stage IIIA Subgroups in Lung Cancer?. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1656-1663.	0.7	5
12	Perfusate adsorption during exÂvivo lung perfusion improves early post-transplant lung function. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, e109-e121.	0.4	30
13	Commentary: Surgery expanding to stage IV non-“small cell lung cancer treatment?!. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1508-1509.	0.4	1
14	Lung volume reduction surgery as salvage procedure after previous use of endobronchial valves. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 263-269.	0.5	5
15	Divided by an ocean of water but united in an ocean of uncertainty: A transatlantic review of mesothelioma surgery guidelines. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1922-1925.	0.4	4
16	Long-Term Outcomes of Cadaveric Lobar Lung Transplantation: An Important Surgical Option. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2021, 27, 244-250.	0.3	0
17	Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC“is it justified?. <i>Translational Lung Cancer Research</i> , 2021, 10, 1-4.	1.3	1
18	Divided by an Ocean of Water but United in an Ocean of Uncertainty: A Transatlantic Review of Mesothelioma Surgery Guidelines. <i>Annals of Thoracic Surgery</i> , 2021, 111, 386-389.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Alterations in <i>BAP1</i> Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2021, 27, 2277-2291.	3.2	21
20	Lymphovascular invasion is an independent prognostic factor for survival in pathologically proven N2 non-small cell lung cancer. <i>Swiss Medical Weekly</i> , 2021, 151, w20385.	0.8	1
21	Subnormothermic Ex Vivo Lung Perfusion Temperature Improves Graft Preservation in Lung Transplantation. <i>Cells</i> , 2021, 10, 748.	1.8	16
22	Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. <i>Acta Neuropathologica</i> , 2021, 141, 901-915.	3.9	28
23	How to prepare for academic leadership: scientific training curriculum. <i>Journal of Thoracic Disease</i> , 2021, 13, 2068-2074.	0.6	2
24	Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. <i>Translational Lung Cancer Research</i> , 2021, 10, 1960-1968.	1.3	12
25	Lung Volume Reduction Surgery in Patients with Homogeneous Emphysema. <i>Thoracic Surgery Clinics</i> , 2021, 31, 203-209.	0.4	1
26	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. <i>Frontiers in Oncology</i> , 2021, 11, 660039.	1.3	28
27	Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 1297-1305.	0.6	9
28	Subnormothermic ex vivo lung perfusion attenuates ischemia reperfusion injury from donation after circulatory death donors. <i>PLoS ONE</i> , 2021, 16, e0255155.	1.1	10
29	CD26 as a target against fibrous formation in chronic airway rejection lesions. <i>Life Sciences</i> , 2021, 278, 119496.	2.0	3
30	Perfluorocarbon-Based Oxygen Carriers and Subnormothermic Lung Machine Perfusion Decrease Production of Pro-Inflammatory Mediators. <i>Cells</i> , 2021, 10, 2249.	1.8	6
31	Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma. <i>Cancer Imaging</i> , 2021, 21, 48.	1.2	6
32	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36
33	Primary Lung Cancer Organoids for Personalized Medicine—Are They Ready for Clinical Use?. <i>Cancers</i> , 2021, 13, 4832.	1.7	4
34	Ex Vivo Lung Perfusion with K(ATP) Channel Modulators Antagonize Ischemia Reperfusion Injury. <i>Cells</i> , 2021, 10, 2296.	1.8	6
35	Women in thoracic surgery: European perspectives. <i>Journal of Thoracic Disease</i> , 2021, 13, 439-447.	0.6	8
36	Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 8-11.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Histology of the pleural rind at [18F]FDG PET/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy. <i>Pathology Research and Practice</i> , 2021, 228, 153660.	1.0	1
38	Perioperative Anaesthesiological Management of Malignant Pleural Mesothelioma Patients Undergoing Extrapleural Pneumonectomy (EPP) and Extended Pleurectomy/Decortication ((E)PD). , 2021, 49, 494-499.		0
39	Quality of Life Is Not Deteriorated After Extrapleural Pneumonectomy vs. (Extended) Pleurectomy/Decortication in Patients With Malignant Pleural Mesothelioma. <i>Frontiers in Surgery</i> , 2021, 8, 766033.	0.6	1
40	Computed tomography radiomics for the prediction of thymic epithelial tumor histology, TNM stage and myasthenia gravis. <i>PLoS ONE</i> , 2021, 16, e0261401.	1.1	11
41	Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 6374.	1.7	4
42	Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 330-340.e4.	0.4	16
43	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
44	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 344-359.	0.5	87
45	Cytosolic pH regulates proliferation and tumour growth by promoting expression of cyclin D1. <i>Nature Metabolism</i> , 2020, 2, 1212-1222.	5.1	11
46	Preoperative Identification of Benefit from Surgery for Malignant Pleural Mesothelioma. <i>Thoracic Surgery Clinics</i> , 2020, 30, 435-449.	0.4	8
47	Functional, Metabolic and Morphologic Results of Ex Vivo Donor Lung Perfusion with a Perfluorocarbon-Based Oxygen Carrier Nanoemulsion in a Large Animal Transplantation Model. <i>Cells</i> , 2020, 9, 2501.	1.8	9
48	Importance of Cullin4 Ubiquitin Ligase in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2020, 12, 3460.	1.7	5
49	Case report of sequential bilateral spontaneous pneumothorax in a never-ventilated, lung-healthy COVID-19-patient. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 441-445.	0.2	10
50	A new lung donor score to predict short and long-term survival in lung transplantation. <i>Journal of Thoracic Disease</i> , 2020, 12, 5485-5494.	0.6	10
51	The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 588563.	1.3	1
52	Extended pleurectomy and decortication with resection and reconstruction of pericardium and hemidiaphragm for malignant pleural mesothelioma. <i>Journal of Visualized Surgery</i> , 2020, 6, 20-20.	0.2	1
53	Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 1166-1172.	0.6	33
54	Complex sleeve lobectomy has the same surgical outcome when compared with conventional lobectomy in patients with lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 860-866.	0.6	9

#	ARTICLE	IF	CITATIONS
55	First Report of a Large Mediastinal Lipoblastoma and its Complete Resection in an Adult: Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 485-487.	0.3	0
56	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2020, 58, 1-24.	0.6	50
57	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal, 2020, 55, 1900953.	3.1	151
58	Identification of target zones for lung volume reduction surgery using three-dimensional computed tomography rendering. ERJ Open Research, 2020, 6, 00305-2020.	1.1	6
59	Postoperative outcome of tracheal resection in benign and malignant tracheal stenosis. Swiss Medical Weekly, 2020, 150, w20383.	0.8	7
60	Dynamic magnetic resonance imaging as an outcome predictor for lung-volume reduction surgery in patients with severe emphysema. European Journal of Cardio-thoracic Surgery, 2019, 55, 446-454.	0.6	4
61	Concomitant Intrathoracic Extrapulmonary and Cervical Hydatid Cyst—a 10-Year Follow-up. SN Comprehensive Clinical Medicine, 2019, 1, 96-98.	0.3	0
62	Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy. Frontiers in Oncology, 2019, 9, 961.	1.3	12
63	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	1.5	10
64	Molecular Research in Chronic Thromboembolic Pulmonary Hypertension. International Journal of Molecular Sciences, 2019, 20, 784.	1.8	19
65	Predictors of blood loss in lung transplant surgery—a single center retrospective cohort analysis. Journal of Thoracic Disease, 2019, 11, 4755-4761.	0.6	8
66	Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2019, 130, 108-114.	0.9	19
67	Intraluminal <i>EWSR1-CREB1</i> gene rearranged, low-grade myxoid sarcoma of the pulmonary artery resembling extraskeletal myxoid chondrosarcoma (EMC).	1.6	6
68	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 744-750.	0.5	20
69	Establishing a non-intubated thoracoscopic surgery programme for bilateral uniportal sympathectomy. Swiss Medical Weekly, 2019, 149, w20064.	0.8	7
70	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncologica, 2018, 57, 1070-1074.	0.8	152
71	Previous lung volume reduction surgery does not negatively affect survival after lung transplantation. European Journal of Cardio-thoracic Surgery, 2018, 53, 596-602.	0.6	17
72	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	0.5	49

#	ARTICLE	IF	CITATIONS
73	Single-center experience with intraoperative extracorporeal membrane oxygenation use in lung transplantation. <i>International Journal of Artificial Organs</i> , 2018, 41, 89-93.	0.7	12
74	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
75	Lung volume reduction surgery in selected patients with emphysema and pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 565-571.	0.6	18
76	Mediastinitis After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of a Follicular Dendritic Cell Sarcoma. <i>Archivos De Bronconeumologia</i> , 2018, 54, 220-221.	0.4	2
77	Outcome After Lung Volume Reduction Surgery in Patients With Severely Impaired Diffusion Capacity. <i>Annals of Thoracic Surgery</i> , 2018, 105, 379-385.	0.7	20
78	Lung volume reduction surgery beyond the NETT selection criteria. <i>Journal of Thoracic Disease</i> , 2018, 10, S2748-S2753.	0.6	13
79	Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema. <i>Journal of Thoracic Disease</i> , 2018, 10, S2704-S2710.	0.6	8
80	Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, S2763-S2774.	0.6	31
81	Surgery in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1638-1654.	0.5	58
82	Lung Transplantation with Controlled Donation after Circulatory Death Donors. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2018, 24, 296-302.	0.3	22
83	Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. <i>Frontiers in Oncology</i> , 2018, 8, 40.	1.3	15
84	Heterogeneity in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1603.	1.8	36
85	Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 6345-6354.	3.2	43
86	Pleural mesothelioma: is the surgeon still there?. <i>Annals of Oncology</i> , 2018, 29, 1710-1717.	0.6	14
87	Chronic thromboembolic pulmonary hypertension. <i>Swiss Medical Weekly</i> , 2018, 148, w14702.	0.8	12
88	A benchmarking project on the quality of previous guidelines about the management of malignant pleural effusion from the European Society of Thoracic Surgeons (ESTS) Pleural Diseases Working Group. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 356-362.	0.6	6
89	SC06.03 Intraoperative Therapies in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S90-S92.	0.5	0
90	P3.03-001 Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1343.	0.5	0

#	ARTICLE	IF	CITATIONS
91	P3.03-044 Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?. Journal of Thoracic Oncology, 2017, 12, S1372-S1373.	0.5	0
92	OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal of Thoracic Oncology, 2017, 12, S247-S248.	0.5	0
93	OA22.07 Correlation of CT Scan Based Tumor Volume Measurement to Actual Resected Tumor Volume - A New T-Factor?. Journal of Thoracic Oncology, 2017, 12, S332-S333.	0.5	0
94	Treatment of limited disease small cell lung cancer: the multidisciplinary team. European Respiratory Journal, 2017, 50, 1700422.	3.1	17
95	Lung transplantation in the elderly: Influence of age, comorbidities, underlying disease, and extended criteria donor lungs. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 2135-2141.	0.4	19
96	Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports, 2017, 7, 16456.	1.6	12
97	Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 1060-1067.	3.2	44
98	Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients. Interactive Cardiovascular and Thoracic Surgery, 2017, 24, 740-746.	0.5	32
99	Curative resection for lung cancer in octogenarians is justified. Journal of Thoracic Disease, 2017, 9, 296-302.	0.6	14
100	A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. Annals of Translational Medicine, 2017, 5, 237-237.	0.7	12
101	Favorable outcome of children and adolescents undergoing lung transplantation at a European adult center in the new era. Pediatric Pulmonology, 2016, 51, 1222-1228.	1.0	20
102	Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons. Interactive Cardiovascular and Thoracic Surgery, 2016, 24, iw373.	0.5	15
103	Clinical Relevance of Our Multimodality Prognostic Score. Journal of Thoracic Oncology, 2016, 11, e39-e40.	0.5	0
104	Impact of time interval between donor brain death and cold preservation on long-term outcome in lung transplantation. European Journal of Cardio-thoracic Surgery, 2016, 50, 264-268.	0.6	3
105	Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Molecular Oncology, 2016, 10, 1255-1265.	2.1	32
106	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2100-2111.	0.5	120
107	Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis. Annals of Thoracic Surgery, 2016, 102, 1680-1686.	0.7	34
108	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2016, 101, 48-58.	0.9	38

#	ARTICLE	IF	CITATIONS
109	Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth <i>In Vivo</i> by Affecting Stroma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1095-1105.	1.9	24
110	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. <i>European Journal of Cancer</i> , 2016, 63, 64-73.	1.3	21
111	MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD. <i>Journal of Molecular Medicine</i> , 2016, 94, 725-734.	1.7	41
112	Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma. <i>Lung Cancer</i> , 2016, 94, 40-45.	0.9	21
113	Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1516-1523.	0.6	41
114	Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 160-165.	0.5	27
115	Hedgehog Signaling in Malignant Pleural Mesothelioma. <i>Genes</i> , 2015, 6, 500-511.	1.0	18
116	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. <i>PLoS Genetics</i> , 2015, 11, e1005633.	1.5	76
117	Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis. <i>PLoS ONE</i> , 2015, 10, e0139312.	1.1	10
118	Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 1539-1547.e1.	0.4	8
119	Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, e34-e41.	0.6	7
120	Induction Therapy for Mesothelioma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 240-249.	0.4	5
121	A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1634-1641.	0.5	59
122	Repeated lung volume reduction surgery is successful in selected patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 710-715.	0.6	22
123	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1651-1658.	5.1	170
124	Surgery versus SABR for resectable non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2015, 16, e372-e373.	5.1	8
125	Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 602-606.	0.6	2
126	European guidelines on structure and qualification of general thoracic surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 779-786.	0.6	42



#	ARTICLE	IF	CITATIONS
127	A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The "SMART" Approach for Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 397-402.	0.5	117
128	PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2014, 9, 239-247.	0.5	30
129	Extrapleural Pneumonectomy After Induction Chemotherapy: Perioperative Outcome in 251 Mesothelioma Patients From Three High-Volume Institutions. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1748-1754.	0.7	41
130	Multimodal management of malignant pleural mesothelioma: where are we today?. <i>European Respiratory Journal</i> , 2014, 44, 754-764.	3.1	44
131	GAS5 long non-coding RNA in malignant pleural mesothelioma. <i>Molecular Cancer</i> , 2014, 13, 119.	7.9	78
132	Management of malignant pleural mesothelioma-The European experience. <i>Journal of Thoracic Disease</i> , 2014, 6 Suppl 2, S238-52.	0.6	49
133	The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. <i>Journal of Thoracic Disease</i> , 2014, 6 Suppl 2, S265-71.	0.6	1
134	Long-term outcomes of bilateral lobar lung transplantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 1220-1225.	0.6	46
135	Minimally invasive resection of thymomas with the da Vinci(R) Surgical System. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 288-292.	0.6	37
136	Perioperative Diclofenac Application during Video-Assisted Thoracic Surgery Pleurodesis Modulates Early Inflammatory and Fibrinolytic Processes in an Experimental Model. <i>European Surgical Research</i> , 2013, 50, 14-23.	0.6	11
137	A clinical-based risk score for decision making for surgery after induction chemotherapy in malignant pleural mesothelioma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7587-7587.	0.8	2
138	Role of Hedgehog Signaling in Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2012, 18, 4646-4656.	3.2	60
139	Sleeve resections with unprotected bronchial anastomoses are safe even after neoadjuvant therapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 77-81.	0.6	43
140	Technique of Pulmonary Thromboendarterectomy. <i>Operative Techniques in Thoracic and Cardiovascular Surgery</i> , 2012, 17, 168-180.	0.2	5
141	Multimodality therapy for malignant pleural mesothelioma. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 502-7.	0.6	20
142	Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model. <i>Lung Cancer</i> , 2011, 71, 370-371.	0.9	4
143	Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis. <i>European Journal of Cancer</i> , 2011, 47, 326-332.	1.3	58
144	Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: A preclinical study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 65-71.	0.4	18

#	ARTICLE	IF	CITATIONS
145	Pleural mesothelioma side populations have a precursor phenotype. <i>Carcinogenesis</i> , 2011, 32, 1324-1332.	1.3	38
146	Editorial comment May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 38, 252-253.	0.6	0
147	Prognostic significance of epithelial to mesenchymal transition in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 566-572.	0.6	83
148	Malignant pleural mesothelioma. <i>Future Oncology</i> , 2009, 5, 391-402.	1.1	10
149	Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. <i>European Journal of Cardio-thoracic Surgery</i> , 2009, 35, 457-462.	0.6	10
150	Functional inactivation of NF2/merlin in human mesothelioma. <i>Lung Cancer</i> , 2009, 64, 140-147.	0.9	139
151	Multimodality Strategies in Malignant Pleural Mesothelioma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2009, 21, 172-176.	0.4	28
152	PTEN expression is a strong predictor of survival in mesothelioma patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 33, 502-506.	0.6	75
153	Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 31, 772-778.	0.6	22
154	P3-020: Combined CCL19/IL-7 treatment eradicates tumors in murine models of lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S615.	0.5	0
155	Influence of Intraperitoneal Application of Taurolidine/Heparin on Expression of Adhesion Molecules and Colon Cancer in Rats Undergoing Laparoscopy. <i>Journal of Surgical Research</i> , 2007, 137, 75-82.	0.8	11
156	Risk Factors for Perioperative Complications in Patients Undergoing Laparoscopic Cholecystectomy: Analysis of 22,953 Consecutive Cases from the Swiss Association of Laparoscopic and Thoracoscopic Surgery Database. <i>Journal of the American College of Surgeons</i> , 2006, 203, 723-728.	0.2	278
157	Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 29, 579-584.	0.6	68
158	Preclinical Comparison of mTHPC and Verteporfin for Intracavitary Photodynamic Therapy of Malignant Pleural Mesothelioma. <i>European Surgical Research</i> , 2006, 38, 333-339.	0.6	13
159	Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats. <i>Lasers in Surgery and Medicine</i> , 2005, 37, 271-277.	1.1	14
160	Bleeding remains a major complication during laparoscopic surgery: analysis of the SALTS database. <i>Langenbeck's Archives of Surgery</i> , 2005, 390, 128-133.	0.8	40
161	Patient selection for radical surgery for mesothelioma: prognostic factors in a multimodality approach. <i>Shanghai Chest</i> , 0, 2, 73-73.	0.3	0